Synairgen plc Stock News

Synairgen PLC (AIM:SNG, OTC:SYGGF) said Joseph Colliver will succeed John Ward as chief financial officer effective November 6. Colliver comes to Synairgen with experience in senior finance and non-

Synairgen PLC (AIM:SNG, OTC:SYGGF) has appointed seasoned pharmaceutical physician and drug developer Dr. Marcin Mankowski as chief medical officer, effective immediately.

London stocks were under pressure on Monday, as investors got whipsawed by updates on the Ukraine-Russia crisis. Syanirgen and Morses were big movers to the

Synairgen announced on Monday that the international phase 3 trial of its SNG001 antiviral inhalation in patients hospitalised with Covid-19 did not meet its primary or key secondary endpoints.

Synairgen stock sinks 85% as COVID-19 treatment misses trial targets Read Full Story The post Synairgen stock sinks 85% as COVID-19 treatment misses trial targets appeared first on ForexTV .

By Joe Hoppe Shares in Synairgen PLC plummeted 85% on Monday after the company said that a Phase 3 trial of its inhaled treatment for Covid-19 failed to meet

This research report will give you deep insights about the Corona Virus Treatment Market and it will also help you in strategic decision making. The final research document is an exhaustive document comprising of 150 pages. All our reports are